Actively Recruiting
A Multicenter Study of the Impact of a COPD Identification and Referral System on Follow Up and Outcomes After an Acute COPD Exacerbation
Led by Viz.ai, Inc. · Updated on 2026-06-03
485
Participants Needed
4
Research Sites
21 weeks
Total Duration
On this page
Sponsors
V
Viz.ai, Inc.
Lead Sponsor
S
Sanofi
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the impact of an AI-enabled clinical workflow tool called Viz COPD on patient follow-up and health outcomes after an acute exacerbation of chronic obstructive pulmonary disease (COPD). This observational study includes patients aged 40 years and older who experience moderate or severe COPD flare-ups requiring emergency department visits or hospitalization. The study collects data both prospectively and retrospectively to compare standard care with care after the tool's implementation. The study has three groups: an experimental cohort of patients seen after the digital health tool was introduced, a control cohort of patients treated before the tool was used, and an exploratory cohort of patients reassessed for specialist follow-up after the tool's implementation. The tool aims to improve referrals to respiratory specialists and monitor treatment consistent with COPD guidelines. Treatment follows usual care, with no investigational drugs or procedures. Participants will be tracked for follow-up visits with respiratory specialists within 30 and 90 days after discharge, and for up to one year in some measures. Researchers will assess rates of readmission, COPD exacerbations, healthcare use, cardiovascular events, and mortality for up to one year after the acute exacerbation. The main focus is on whether the AI tool improves timely specialist follow-up and patient outcomes after a serious COPD episode.
CONDITIONS
Brief Title
COPD Exacerbation Follow Up
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 40 years or older at the time of arrival to the emergency department
- Clinical diagnosis of COPD with a moderate or severe exacerbation
- Moderate exacerbation requiring systemic corticosteroids and/or antibiotics
- Severe exacerbation requiring hospitalization, observation over 24 hours in emergency/urgent care, or resulting in death
- Use of dual or triple long-acting bronchodilator inhalers
You will not qualify if you...
- Use of bronchodilator inhaler monotherapy
- Leaving against medical advice or death during hospitalization
- Presence of tracheostomy
- Advanced cancer
- Previous lung transplant
- Discharge to hospice care
- Transfer to another hospital
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year after discharge
Participants are observed following an acute COPD exacerbation to assess follow up with respiratory specialists and health outcomes.
Follow-up visits depending on cohort and clinical care
Trial Site Locations
Total: 4 locations
1
Advocate Lutheran General Hospital
Park Ridge, Illinois, United States, 60068
Not Yet Recruiting
2
Cooper University Health Care
Cherry Hill, New Jersey, United States, 08002
Actively Recruiting
3
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
Actively Recruiting
4
Aurora St. Luke's Medical Center
Milwaukee, Wisconsin, United States, 53215
Not Yet Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here